Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have received a consensus rating of “Hold” from the ten research firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $18.00.

A number of brokerages recently issued reports on AMPH. Piper Jaffray Companies set a $20.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, July 29th. BidaskClub downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. BMO Capital Markets reissued a “hold” rating and set a $16.00 price target on shares of Amphastar Pharmaceuticals in a research report on Monday, July 31st. ValuEngine downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $19.00 price target (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th.

WARNING: “Amphastar Pharmaceuticals, Inc. (AMPH) Receives Average Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/16/amphastar-pharmaceuticals-inc-amph-receives-average-rating-of-hold-from-analysts.html.

Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) traded down 0.32% during mid-day trading on Friday, reaching $15.73. The company had a trading volume of 303,542 shares. The firm’s 50 day moving average is $15.66 and its 200-day moving average is $15.80. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $21.75. The stock has a market capitalization of $726.65 million, a P/E ratio of 204.29 and a beta of 1.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.05. The company had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 earnings per share. On average, analysts expect that Amphastar Pharmaceuticals will post $0.27 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals announced that its Board of Directors has initiated a share buyback program on Wednesday, August 9th that authorizes the company to buyback $20.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $14.80, for a total value of $74,000.00. Following the sale, the director now owns 33,844 shares of the company’s stock, valued at approximately $500,891.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $14.81, for a total value of $148,100.00. Following the completion of the sale, the director now directly owns 33,844 shares in the company, valued at approximately $501,229.64. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after purchasing an additional 842 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $111,000. State of Alaska Department of Revenue boosted its holdings in shares of Amphastar Pharmaceuticals by 77.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 7,052 shares of the company’s stock valued at $125,000 after purchasing an additional 3,072 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in shares of Amphastar Pharmaceuticals by 3.7% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 8,200 shares of the company’s stock valued at $119,000 after purchasing an additional 290 shares in the last quarter. Finally, Mason Street Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 7.0% in the 1st quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after purchasing an additional 549 shares in the last quarter. 44.51% of the stock is currently owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.